Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer

被引：23
作者：
Ryan, Kellie J. [1 ]
Skinner, Karen E. [2 ]
Fernandes, Ancilla W. [1 ]
Punekar, Rajeshwari S. [2 ]
Pavilack, Melissa [1 ]
Walker, Mark S. [2 ]
VanderWalde, Noam A. [3 ]
机构：
[1] AstraZeneca, 101 Orchard Ridge Dr,3233D, Gaithersburg, MD 20878 USA
[2] Vector Oncol, 6555 Quince,Suite 400, Memphis, TN 38119 USA
[3] Univ Tennessee, Hlth Sci Ctr, West Canc Ctr, 7945 Wolf River Blvd, Germantown, TN 38138 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 25期
关键词：
community oncology; concurrent chemoradiation; real-world; sequential chemoradiation; treatment patterns; unmet need; unresected stage III NSCLC; CONCURRENT; SURVIVAL;
D O I：
10.2217/fon-2018-0939
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Little is known about recent treatment patterns among patients with unresected stage III NSCLC in the real world. This retrospective study used medical records from USA community oncology practices to address this knowledge gap. Materials & methods: Eligible patients were stage III NSCLC adults diagnosed between 1 January 2011 and 1 March 2016 without surgical resection. Treatment patterns were assessed across three progression intervals, from stage III diagnosis through third progression. Results: The most common regimen in interval 1 was platinum doublet chemotherapy + radiation therapy, in interval 2 was chemotherapy only, and in interval 3 was non-platinum chemotherapy monotherapy. Conclusion: Most patients were treated following national guidelines, but important unmet needs remain.
引用
收藏
页码：2943 / 2953
页数：11
相关论文
共 20 条
  • [1] [Anonymous], 2018, NCCN Clinical Practice Guidelines in Oncology
  • [2] [Anonymous], 2009, AJCC CANC STAGING MA
  • [3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [4] Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC):: A meta-analysis of individual data from 1764 patients
    Aupérin, A
    Le Péchoux, C
    Pignon, JP
    Koning, C
    Jeremic, B
    Clamon, G
    Einhorn, L
    Ball, D
    Trovo, MG
    Groen, HJM
    Bonner, JA
    Le Chevalier, T
    Arriagada, R
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (03) : 473 - 483
  • [5] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
    Auperin, Anne
    Le Pechoux, Cecile
    Rolland, Estelle
    Curran, Walter J.
    Furuse, Kiyoyuki
    Fournel, Pierre
    Belderbos, Jose
    Clamon, Gerald
    Ulutin, Hakki Cuneyt
    Paulus, Rebecca
    Yamanaka, Takeharu
    Bozonnat, Marie-Cecile
    Uitterhoeve, Apollonia
    Wang, Xiaofei
    Stewart, Lesley
    Arriagada, Rodrigo
    Burdett, Sarah
    Pignon, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190
  • [6] Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non-Small-Cell Lung Cancer
    Berry, Mark F.
    Worni, Mathias
    Pietrobon, Ricardo
    D'Amico, Thomas A.
    Akushevich, Igor
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (06) : 744 - 752
  • [7] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Bradley, Jeffrey D.
    Paulus, Rebecca
    Komaki, Ritsuko
    Masters, Gregory
    Blumenschein, George
    Schild, Steven
    Bogart, Jeffrey
    Hu, Chen
    Forster, Kenneth
    Magliocco, Anthony
    Kavadi, Vivek
    Garces, Yolanda I.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Cliff
    Wynn, Raymond B.
    Koprowski, Christopher
    Meng, Joanne
    Beitler, Jonathan
    Gaur, Rakesh
    Curran, Walter, Jr.
    Choy, Hak
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 187 - 199
  • [8] Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
    Curran, Walter J., Jr.
    Paulus, Rebecca
    Langer, Corey J.
    Komaki, Ritsuko
    Lee, Jin S.
    Hauser, Stephen
    Movsas, Benjamin
    Wasserman, Todd
    Rosenthal, Seth A.
    Gore, Elizabeth
    Machtay, Mitchell
    Sause, William
    Cox, James D.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (19) : 1452 - 1460
  • [9] Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer
    Davidoff, Amy J.
    Gardner, James F.
    Seal, Brian
    Edelman, Martin J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 934 - 941
  • [10] Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
    Dillman, RO
    Herndon, J
    Seagren, SL
    Eaton, WL
    Green, MR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) : 1210 - 1215
12